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highlights
• Gb3 and Lyso-Gb3, plasma lipids accumulating in Fabry disease, cause mechanical allodynia in mice.
• Lyso-Gb3 elevates intracellular calcium level in sensory neurons.
• Lyso-Gb3 enhances voltage-dependent calcium currents in small-diameter DRG neurons.
• Direct effects of lyso-Gb3 on sensory neurons may contribute to the pain of Fabry disease.
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abstract
Fabry disease is an X-linked lysosomal storage disorder characterised by accumulation of glycosphin-
golipids, and accompanied by clinical manifestations, such as cardiac disorders, renal failure, pain and
peripheralneuropathy.Globotriaosylsphingosine(lyso-Gb3),adeacylatedformofglobotriaosylceramide
(Gb3),hasemergedasamarkerofFabrydisease.WeinvestigatedthelinkbetweenGb3,lyso-Gb3andpain.
Plantar administration of lyso-Gb3 or Gb3 caused mechanical allodynia in healthy mice. In vitro appli-
cation of 100nM lyso-Gb3 caused uptake of extracellular calcium in 10% of sensory neurons expressing
nociceptor markers, rising to 40% of neurons at 1M, a concentration that may occur in Fabry disease
patients. Peak current densities of voltage-dependent Ca2+ channels were substantially enhanced by
application of 1M lyso-Gb3. These studies suggest a direct role for lyso-Gb3 in the sensitisation of
peripheral nociceptive neurons that may provide an opportunity for therapeutic intervention in the
treatment of Fabry disease-associated pain.
© 2015 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Fabry disease (OMIM 301500) is a lysosomal storage disorder
caused by a deﬁciency or absence of the enzyme -galactosidase
A, due to mutations of the X-linked gene GLA [1]. As a result,
unmetabolised glycosphingolipids accumulate in various types of
Abbreviations: Gb3, globotriaosylceramide; Lyso-Gb3, lyso-
globotriaosylceramide; GLA, gene encoding alpha galactosidase A; HBSS, HEPES
buffered saline; PBS, phosphate buffered saline.
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cells including neurons of the dorsal root ganglia (DRG) [2]. Accu-
mulation in the lysosomes of vascular endothelial cells contributes
toacharacteristicrenalandcardiovascularpathology.Neuropathic
pain,typicallyasensationofburning,itchingorshootingpaininthe
hands and feet, is an early symptom of Fabry disease [2–4]. How-
ever, little is known about the direct effects of accumulated lipids
on neuronal function.
Amongtheglycosphingolipidswhicharefoundtobeelevatedin
patients with Fabry disease, globotriaosylceramide (Gb3) has been
recognised as a diagnostic and predictive marker [5]. However,
recent studies suggest the existence of other factors in addition
to Gb3, since GLA enzyme replacement therapy for clearance of
excessive Gb3 does not result in remission, and Gb3 levels do
not always correlate with severity [6]. Globotriaosylsphingosine
(lyso-Gb3), a deacylated form of Gb3, has emerged as a good
biomarker for Fabry disease since a robust increase in plasma in
both patients and animal models has been reported [7]. Lyso-Gb3
has been proposed to play a causative role in Fabry disease
http://dx.doi.org/10.1016/j.neulet.2015.01.084
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pathogenesis by accelerating Gb3 storage [7]. In GLA null mutant
mice and in Fabry patients, the drug migalastat-HCl lowers plasma
levels of lyso-Gb3, which suggests that the lyso marker is clinically
relevant [8,9], although phase III drug trial endpoints were not
met [10]. Migalastat both mimics the terminal galactose on Gb3,
and stabilises the structure of mutant GLA, while it is targeted
to the lysosome where Gb3 can be metabolised. However, the
contribution of lyso-Gb3 to Fabry pain is uncertain.
Pain is a response to noxious stimuli, such as cold or heat,
mechanical stress or the signals arising during inﬂammation. The
noxious stimulus is detected by peripheral damage-sensing neu-
rons (nociceptors). The depolarisation of the nociceptor is usually
linked to an increase in cytosolic Ca2+ levels [19]. Although accu-
mulation of lipids in DRG has been reported in Fabry patients [2],
the effect of elevated glycosphingolipids on sensory neuron func-
tion has not been investigated. We therefore, examined whether
lyso-Gb3 functionally affects nociceptive neurons to determine if
thereisacausallinkbetweenthemarkerlyso-Gb3andpaininFabry
disease.
2. Material and methods
2.1. Animals
All experiments were approved by the UCL ethics board with
prior approval by the UK home ofﬁce. C57/BL6 mice (Charles River,
UK) were treated in accordance with the UK Animal (Scientiﬁc Pro-
cedures) Act 1986.
2.2. Von Frey test
Mechanical withdrawal thresholds were measured by applying
von Frey hairs (Stoelting, Wood Dale, USA) to the plantar surface
of the hindpaw. The 50% paw withdrawal threshold was calculated
using the up-and-down method [11]. Animals received a plantar
injection of Gb3, lyso-Gb3 or saline (20l) 30min prior to testing.
All experiments were performed blind to treatment.
2.3. Adult DRG neuronal culture
DRG from all spinal levels were dissected from adult 7–8 week
oldmiceandculturedaspreviouslydescribed[12].Dissociatedcells
were plated on 1g/ml poly-l-lysine and 0.02mg/ml laminin pre-
coated either 15mm cover slips (for calcium imaging) or 35mm
petri dishes (for whole-cell patch clamp recording).
2.4. Calcium imaging
Plated DRG cells were washed with Ca2+ recording buffer con-
sisting of (in mM) 140 NaCl2, 4 KCl, 2CaCl2,1M g C l 2, 10 HEPES, 10
glucose adjusted to pH 7.4 and osmolality 320mOsm/l using NaOH
and sucrose, respectively. Cells were incubated in recording buffer
with 2.5M Fura-2AM (Invitrogen, UK) for 30min at room tem-
perature. In some experiments, cells were pre-treated with 5g/l
IB4-FITC (Sigma, UK) in culture medium at 37 ◦C for 20min before
Fura-2AM loading. Cells were washed twice with Ca2+ recording
buffer for 5min each time at room temperature to remove excess
Fura-2AM. A coverslip of cells was placed over the window of a SA-
NIK stage adapter (Warner Instruments). The perfusing chamber
wastightenedontotheadapter,withvacuumgreasesilicone(Beck-
man, USA) to enhance the seal. 0.5ml of Ca2+ recording buffer was
loaded onto the perfusing chamber before the whole assembly was
mounted onto the stage of a Nikon Eclipse TE300 microscope. The
inlet tube of a perfusing system (cFlow 8 Channel Flow Controller,
Cell Micro Controls, USA) was connected to the recording cham-
ber, and the speed of superfusate was set to 250l/min. Images
were obtained using either a 20× or 40× (oil immersion) Nikon
objective, equipped with ﬂuorescent ﬁlter sets. A Till polychrome
II monochromator was used to excite the ﬂuorescence of Fura-2
at 340nm and 380nm, and data were acquired using OptoFluor
software (Cairn Research, UK). Fura-2AM emission was collected at
505nm.
2.5. Electrophysiology
Whole-cell patch-clamp recordings were performed at room
temperature using an Axopatch 200B ampliﬁer and Digidata board
1320A controlled by pClamp v9.0 software (Axon Instruments,
Molecular Devices Inc.). Recording pipettes were pulled from
borosilicate glass microcapillaries (Intracel Ltd., Herts, UK) with
a range of pipette resistances between 2 and 4M  after ﬁlling
with intracellular solution consisting of (in mM) 146 CsCl2, 1 CaCl2,
4 MgCl2, 10 HEPES–Na, 10 EGTA, 4.5 MgATP and 0.4 GTP–Na,
adjusted to pH 7.3 and osmolarity 300mOsm/l using CsOH and
sucrose,respectively.Recordingswereperformedinvoltage-clamp
mode and currents were low-pass ﬁltered at 5kHz and sampled at
10kHz. Values for series resistance (Rs) and capacitance (Cm) were
read directly from the ampliﬁer after subtraction of capacitative
transients. Series resistances were compensated to the maximum
extent possible (usually 60–75%) and voltages were not corrected
for liquid junction potentials. External solution consisting of (in
mM) 162.5 tetraethylammonium (TEA)–Cl, 5 CaCl2, 1 MgCl2,1 0
glucose and 10 HEPES with pH adjusted to 7.4 using TEA–OH was
used to isolate calcium currents. Lyso-Gb3 was applied to cells via
a perfusing system and the speed of perfusing solution was set
at 1ml/min. Only small-diameter DRG neurons (with capacitance
less than 25pF) were chosen for recording. Off-line data analysis
was performed using ClampFit v9.0 software (Axon Instruments,
Molecular Devices Inc.).
Drugsstocks of Fura-2AM (Invitrogen, UK) and lyso-Gb3 (Sigma,
UK) were dissolved in DMSO and HBSS containing 2mM Ca2+ and
1mMMg 2+, respectively. Stocks of capsaicin (8-methyl-N-vanillyl-
trans-6-nonenamide, Sigma, UK) were prepared in ethanol. For
intraplantar administration, Gb3 or lyso-Gb3 (Matreya LLC, UK)
werepreparedinsaline.50mMKClwaspreparedinCa2+ recording
buffer on the same day for use.
2.6. Statistical analysis
One way ANOVA was followed by a Bonferroni post-hoc test
when statistical signiﬁcance was observed. Comparison between
two groups was performed with independent samples T-test, and
a Student’s paired T-test was used to compare two different condi-
tions in the same cell unless otherwise stated. Data were presented
as the mean±SEM. All statistical analyses were performed using
Prism 5 for Windows.
3. Results
3.1. Treatment with Gb3 or lyso-Gb3 induces mechanical
allodynia in healthy mice
We administered 20lo f3 0M Gb3 or lyso-Gb3 to the hind
paws of wild type mice and tested sensitivity at different time
points. As seen in Fig. 1A, both Fabry lipids signiﬁcantly reduced
pain thresholds compared to saline (P<0.05). The increased sensi-
tivity lasted up to 6h. All the mice completely recovered from the
acute mechanical allodynia 24h post injection.
3.2. Exogenous lyso-Gb3 increases intracellular Ca2+ in sensory
neurons
We next examined the cellular actions of lyso-Gb3 on DRG
sensory neurons in culture. We investigated the effect of apply-L. Choi et al. / Neuroscience Letters 594 (2015) 163–168 165
Fig. 1. Effects of lyso-Gb3 on pain sensitivity and intracellular Ca2+ levels in nociceptive DRG neurons.
(A) Either Gb3 or lyso-Gb3 injected into mice hind paws signiﬁcantly enhanced pain sensitivity to mechanical stimuli over several hours post injection (n=6–9 per group).
Sensitivity resolved to a normal level within 24h. Repeated measures ANOVA revealed effects of time: F (6,126)=7.551, P<0.0001, and of Fabry lipids (F (21,126)=3.089,
P<0.001) but no difference between the two lipids (effect of lipid type: F (2,126)=6.179, P<0.05).
(B) Lyso-Gb3 evoked an increase in cytoplasmic Ca2+ levels in DRG neurons in a dose-dependent manner. The concentration of lyso-Gb3 producing changes in Ca2+ levels is
plotted against the percentage of responsive DRG neurons. (C) Repetitive applications of lyso-Gb3 (1M), but not vehicle evoked transient increases in Ca2+ levels in DRG
neurons. (D) Representative real time recordings of the changes in Fura-2 ratio acquired every 10s in individual DRG neurons during bath applicationso f1M Lyso-Gb3,
50mM KCl and 1M capsaicin. (E) Statistical summary of the changes in Fura-2 ratio before and after application of 1M of lyso-Gb3 (n=74). *P<0.05 and **P<0.0001.
ing lyso-Gb3 on the levels of intracellular Ca2+ of DRG neurons.
Increased Ca2+ levels were observed following lyso-Gb3 applica-
tion at concentrations higher than 0.1M( Fig 1B). Concentrations
between 0.1 and 1M are found in Fabry disease patients with
clinical manifestations [13,14]. Our results indicate that clin-
ical lyso-Gb3 concentrations cause a concentration-dependent
increase in Ca2+ levels in the cytoplasm of sensory neurons. We
then used 1M lyso-Gb3 to test if repetitive application of lipid
could trigger a repetitive rise in intracellular Ca2+ level in DRG
neurons. Fig. 1C demonstrates that whilst applications of vehi-
cle alone did not affect basal Ca2+ levels, 1M lyso-Gb3 applied
three times evoked transient increases in Ca2+ levels. Administra-
tion of high-potassium-containing medium (KCl, 50mM) evoked
a depolarization-mediated rise in intracellular Ca2+ level in every
testedneuron(Fig.1CandD).AllDRGneuronsshowinganincrease
in Ca2+ levels following lyso-Gb3 application and responding to
50mM of KCl were capsaicin-sensitive as shown by an increase
in cytoplasmic Ca2+ levels during application of 1M capsaicin
(Fig. 1D).
3.3. Lyso-Gb3 increases intracellular Ca2+ in capsaicin-sensitive
peptidergic neurons
Sensoryneuronscanbeclassiﬁedusingarangeofmorphological
and functional criteria. Small diameter sensory neurons, many of
which are nociceptors, can be subdivided into peptidergic neurons166 L. Choi et al. / Neuroscience Letters 594 (2015) 163–168
Fig. 2. Identiﬁcation of the DRG neuron population responsive to lyso-Gb3.
(A) Distribution of cells according to diameter; lyso-Gb3 responders were all small-diameter cells, as were 89 % of capsaicin-responsive cells. The third bar of the histogram
signiﬁes that IB-4 positive cells were all small-diameter neurons. (B) Lyso-Gb3 responsive cells were all stimulated by 1M capsaicin, but only 17 % of these bound IB-4. (B)
Other lyso-Gb3 responsive capsaicin-sensitive cells were IB-4 negative. (C) Statistical summary of the lyso-Gb3-induced changes in Fura-2 ratio in neuronal subgroups shows
no signiﬁcant difference between IB4-positive and IB4-negative DRG neurons. (D) Representative images showing the changes in Fura-2 ﬂuorescence during application of
lyso-Gb3,KClorcapsaicininIB4-positiveDRGneurons.ArrowspointtotheIB4-positiveneurons.(E)Subpopulationoflyso-Gb3-respondingneuronsrepresentsapproximately
63% of capsaicin-sensitive DRG neurons, only 17% of those were positive for IB-4 binding. **P<0.0001.
Fig. 3. Requirement for extracellular calcium in the Fura-2 response to lyso-GB3.
(A) Representative real time traces showing intracellular Ca2+ levels following superfusion with lyso-Gb3 in either Ca2+ free or standard recording buffer containing 2mM
Ca2+.(B)PeakFura-2AM340/380ratiobetweenbaselineandlyso-Gb3.CellsappearredinaccordancewithCa2+ levels.(C)Representativeﬂuorescentimagesshowingchanges
in Ca2+ levels.
Note: Data sampled every 10s during calcium imaging. **P<0.0001.L. Choi et al. / Neuroscience Letters 594 (2015) 163–168 167
Fig. 4. Effects of lyso-Gb3 on Ca2+ inﬂux and current density of voltage-activated Ca2+ channels in DRG neurons.
(A) Representative traces of Ca2+ currents evoked in the same small-diameter DRG neuron by voltage steps from holding potential (Vh) –70mV to test potential (Vt) from
–60mV to +50mV in 5mV increments before (top) or during (medium) application of 1M lyso-Gb3 via a perfusion system. Ca2+ currents (bottom) in the presence of
lyso-Gb3 were completely inhibited by 50M CdCl2. Inset illustrates the voltage-clamp protocol used to elicit currents. (B) Representative Ca2+ currents recorded at Vt 0mV
before (control) and after lyso-Gb3 application. (C) Average current–voltage relationships of Ca2+ currents before and during an application of 1M lyso-Gb3. The peak
current amplitudes at each Vt were normalized to cell capacitance and expressed as the current density. (D) A statistical summary of the current densities at Vt 0mV before
and during lyso-Gb3 application. Changes in current density were normalized to control.. *P<0.05 (paired t-test).
that do not bind the lectin IB4 and another subset that express c-
Ret that do bind IB4. [15,16]. These two subsets of sensory neurons
have been found to show functional differences [15]. We examined
the subgroups of lyso-Gb3 responsive DRG neurons using calcium
imagingcombinedwithIB4labelling.Wemeasuredthesizeofcells
which showed at least a 30% increase in Fura-2 ratio following a
1min superfusion with lyso-Gb3. The lipid responsive cells were
identiﬁed as small-diameter neurons (Fig. 2A), responsive to 1M
capsaicin and predominantly negative for IB4 staining – in other
words peptidergic neurons (Fig. 2B). However, the average lyso-
Gb3-evoked changes in Fura-2 ratio did not differ between IB4-
positive and IB4-negative small-diameter DRG neurons (Fig. 2C).
Fig. 2E illustrates the overlapping subpopulations detected in these
experiments.
Fig. 3A shows that increased intracellular Ca2+ inﬂux occurred
only in the presence of Ca2+ in the recording buffer, indicating that
the source for increased cytoplasmic Ca2+ was the extracellular
solution and not intracellular stores.
3.4. Lyso-Gb3 increases the current density of voltage-dependent
Ca2+ channels in small-diameter DRG neurons
Next we examined whether the lyso-Gb3-evoked increases
in cytoplasmic Ca2+ levels were mediated by effects on voltage-
activated Ca2+ channels, known to control Ca2+ entry during
neuronal depolarisation [17]. To assess how lyso-Gb3 affects
voltage-activated Ca2+ currents in nociceptive DRG neurons, we
recorded inward Ca2+ currents in small-diameter DRG before (con-
trol) and during application of lyso-Gb3 by eliciting currents with
a set of 250-ms voltage steps from −60 to +50mV (Vt)i n5 m V
increments(holdingpotential:–70mV,seeFig.4Atop).Inthepres-
enceof1Mlyso-Gb3,Ca2+ currentsweresigniﬁcantlyaugmented
in small-diameter DRG neurons at most of the tested membrane
potentials (Fig. 4A and B). Furthermore, the current density of
voltage-activated Ca2+ currents was signiﬁcantly increased from
Vt −15mV to +35mV (n=8/membrane potential; P<0.05; Fig. 4C
and D). In the presence of vehicle for lyso-Gb3 there was no signif-
icant change in current before and during the application (data not
shown).
4. Discussion
This study investigated a potential link between high levels of
the Fabry lipid lyso-Gb3 and pain. In healthy mice administra-
tion of lyso-Gb3 induced mechanical allodynia. In peptidergic DRG
neurons, lyso-Gb3 evoked an increase in intracellular Ca2+ levels
associated with the functional upregulation of voltage-activated
Ca2+ channels.
Plasma circulation of lyso-Gb3 and the concomitant lysosomal
accumulation of Gb3 have been proposed to lead to pain in Fabry
disease [7], and our study provides evidence consistent with this,
by showing that healthy mice receiving plantar injections of Gb3168 L. Choi et al. / Neuroscience Letters 594 (2015) 163–168
or lyso-Gb3 developed mechanical allodynia. This observation is
consistent with direct sensitization of DRG neurons following inﬁl-
tration of lysoGb3 into plasma. We found that lyso-Gb3 triggers
a rise in intracellular Ca2+ levels in a subpopulation of DRG neu-
rons that express markers associated with damage sensing. The
origin of excessive lysoGb3 is not clearly identiﬁed, although drugs
that stabilise the GLA enzyme also reduce the levels of lyso-Gb3 in
plasma [9] suggesting that lyso-Gb3 is a direct product of normal
lipid catabolism rather than the outcome of degradation.
This study is the ﬁrst to show a direct link between lyso-Gb3,
intracellular changes in peripheral sensory neurons and pain. The
pain syndrome in Fabry disease was thought to arise from small
ﬁbre dysfunction, such as length dependent neuropathy which is
typically linked to a loss or decrease of myelinated A ﬁbres and
unmyelinated C ﬁbres [4]. However, it is not known whether the
exposure to or accumulation of lipids directly causes small nerve
ﬁber damage [18], and our study did not investigate any neuro-
pathic effects of lyso-Gb3. Nevertheless the possibility of small
nerve ﬁbre damage by lyso-Gb3 exists, given that promoted Ca2+
inﬂux may cause Ca2+-dependent excitotoxicity [19]. Our study
showed that only high concentrations of lyso-Gb3 equivalent to
the level in pre-treated Fabry patients evoked Ca2+ rises in small-
diameterDRGneuronsoftheIB4nonbinding,peptidergicsub-class.
Intracellular Ca2+ signalling regulates many cellular functions.
In the present study, 1M lyso-Gb3, a possible concentration
reported in patients with Fabry disease [13], was shown to induce
a promoted membrane Ca2+ inﬂux. Further, the lipid enhanced
voltage-dependent Ca2+ current densities, indicating functional
upregulation of voltage-dependent Ca2+ channels as a plausi-
ble mechanism of functional changes in peripheral nociceptors.
Voltage-dependent Ca2+ channels in DRG neurons play a role in
transmission of nociceptive signals from the periphery, and neuro-
pathicmanifestationsincludingincreasedpainsensitivityhavealso
been shown to be associated with increased Ca2+ entry in disease
states, such as diabetes [20].
This is the ﬁrst report showing the onset of mechanical
allodynia, and augmented Ca2+ inﬂux mediated by upregulated
voltage-dependent Ca2+ channels in nociceptive DRG neurons, fol-
lowing lyso-Gb3 administration. This study shows that Fabry lipids
may cause pain through direct actions on sensory neurons, and
that promoted Ca2+-dependent excitability of nociceptors is a pos-
sible mechanism. These observations support further investigation
oftheeffectsofFabry-diseaseassociatedlipidsonionﬂuxesinsen-
sory neurons and their potential signiﬁcance in the pain associated
with this condition.
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